Empowering Medical Aesthetic Clinics, Practitioners, and Patients

Understanding Weight Gain while on Ozempic®

Last updated: September 2026

Ozempic®, whose active ingredient is semaglutide, is prescribed to adults with type 2 diabetes. Like all medications it has side effects, and some people report the apparently paradoxical one: the scale going up rather than down. If the number is climbing while you are on treatment, something specific is usually happening, and in most cases it can be identified and addressed.

Weight gain is not a recognised effect of semaglutide itself. It is not listed in the prescribing information, and across the clinical trial programme semaglutide produced weight loss rather than weight gain. What the evidence does explain, in detail, is the handful of situations in which weight rises anyway: a dose that has not reached its target, another medication working in the opposite direction, the natural plateau that arrives at about a year, muscle lost along with fat, and weight returning after treatment stops. This guide covers each one, with the trial numbers behind it. If the issue is that the scale has simply stopped moving, our companion guide on why weight loss stalls on Ozempic® covers that side of the question.

Key Takeaways

Can Ozempic® cause weight gain?

Not directly. Semaglutide slows stomach emptying, increases the feeling of fullness and reduces appetite, and in every major trial it produced weight loss. Weight gain does not appear as a side effect in the Ozempic® prescribing information.

Some patients do see the scale rise during treatment, and that experience is real. What is happening in almost every case is that something else is pushing in the opposite direction, or the weight being measured is not what it appears to be. The rest of this guide works through those explanations in the order a clinician would consider them.

Ozempic® is not the weight-loss version of semaglutide

This is the distinction that explains the most confusion, and it is worth stating plainly before anything else. Ozempic® is approved for glycemic control in type 2 diabetes, for reducing cardiovascular risk in type 2 diabetes with established heart disease, and, since January 2025, for slowing kidney disease in type 2 diabetes with chronic kidney disease. It is not approved for weight loss. The same molecule is sold as Wegovy® for chronic weight management, at higher doses.

Type 2 diabetes itself also blunts the response. In STEP 2, semaglutide 2.4 mg produced 9.6% weight loss in people with type 2 diabetes, against 3.4% on placebo — compared with roughly 15% in STEP 1, where participants did not have diabetes. A patient with diabetes whose weight moves slowly is seeing the expected pattern. For the wider clinical picture on the weight-management side of semaglutide, see our overview of semaglutide for weight loss for providers.

What factors contribute to weight gain when on Ozempic®?

Several things can push weight up during treatment, and they often overlap. The table below lists them roughly in the order a prescriber would work through them.

How is weight gain associated with Ozempic®’s impact on the body?

Semaglutide works by mimicking GLP-1, a hormone the gut releases after eating. It prompts insulin release when blood glucose is high, suppresses glucagon, slows gastric emptying and acts on appetite centres in the brain. Importantly for this question, it improves insulin sensitivity rather than reducing it, and it does not promote fat storage.

So the medication is not adding weight through its own mechanism. Where its physiology can contribute indirectly is through side effects. If nausea leads someone to switch to bland, calorie-dense foods that settle the stomach, or if fatigue during titration reduces activity, intake and expenditure can move the wrong way. Both are manageable and both are temporary for most people. If gastrointestinal side effects are severe enough to be reshaping the diet, that is a reason to slow titration, not to accept the weight change.

Why weight loss plateaus after about a year

The SELECT trial followed 17,604 adults on semaglutide 2.4 mg for four years. Weight loss continued for about 65 weeks, then held steady for the remaining three years: an average of 10.2% below starting weight at four years, against 1.5% on placebo, with waist circumference down 7.7 cm.

Two things follow from that, and both matter to anyone searching this question at the one- or two-year mark. First, a scale that stops moving at about a year is the expected pattern, not a sign the medication has stopped working. Second, once the plateau is reached, the loss holds for as long as treatment continues. Think of it as a thermostat reaching its setting rather than a furnace breaking down: the room stops getting warmer because it has arrived.

Small movements up and down after that point are normal — fluid, food volume, bowel habit, hormonal cycles and muscle all register on a bathroom scale. A steady upward trend over several weeks is different, and that is when the checks in the previous section are worth working through.

How can weight gain induced by Ozempic® be mitigated?

Managing it means finding which of the causes above applies, rather than working harder at diet and exercise in isolation. In practice that means:

• Review every other medication with the prescriber, including ones started long before the semaglutide.
• Confirm the dose and the schedule. Is titration complete, and are doses landing weekly? A missed dose can be taken within 5 days; after that the label says to skip it.
• Protect muscle. Adequate protein and resistance training change the composition of what is lost, which changes what the scale does later.
• Address the gut. Constipation is common, easily treated, and worth ruling out before drawing conclusions from a few pounds.
• Look at drinks. Alcohol and calorie-containing drinks bypass most of the appetite effect.
• Check thyroid function and other conditions that alter metabolism.
• Give it time at a full dose. Twelve to sixteen weeks on the target dose is a reasonable point to reassess.

Adjusting the dose, switching products or adding another medication are all decisions for the prescriber, not changes to make independently.

Does everyone experience weight gain on Ozempic®?

No. The large majority of people lose weight. What varies is how much, and a minority see very little.

In the major trials, roughly 10–15% of participants did not lose even 5% of their starting body weight. Contributing factors include thyroid disease, other metabolic conditions, a starting BMI above 40, and dietary pattern. Women tend to lose somewhat more than men. Limited response is not the same as gaining weight, but it can feel similar to someone watching the scale, and it deserves a proper reassessment rather than a quiet increase in dose.

How rapid is the weight gain when on Ozempic®?

It depends entirely on the cause. Weight that appears within days is almost always fluid or gut contents, and it moves back out again. Weight from a medication that promotes fat storage, or from a diet shifted by nausea, accumulates gradually over weeks and months.

The fastest and best-documented pattern is the one that follows stopping treatment. A 2026 BMJ meta-analysis of 37 studies and 9,341 participants found that after stopping semaglutide or tirzepatide, weight returned at about 0.8 kg a month — roughly 9.9 kg in the first year, and back to starting weight in about 18 months on average. Across all weight-loss medications the average pace was slower, around 0.4 kg a month, with return to baseline in about 1.7 years.

How much weight can an individual gain when using Ozempic®?

While treatment continues at a full dose, most people do not gain; they lose and then hold. The meaningful numbers concern what happens after treatment ends:

• STEP 1 trial extension. Participants lost 17.3% of their body weight over 68 weeks on semaglutide. In the year after stopping, they regained 11.6 percentage points of it, finishing 5.6% below where they started. Improvements in blood pressure, lipids and blood sugar drifted back toward baseline as well.
• STEP 4. After 20 weeks of treatment, people who continued lost a further 7.9% over the next 48 weeks, while those switched to placebo gained 6.9% back — a 14.8-point difference driven by nothing except stopping.

Cost, supply problems and side effects are the usual reasons treatment stops, so planning for continuation is part of planning the treatment. Our guides on what happens when you stop taking Ozempic® and on keeping weight off after stopping a GLP-1 cover this in more depth.

Muscle, fluid, and what the scale is actually measuring

A bathroom scale reports one number for several different things. That matters here, because body composition changes during GLP-1 treatment in a way the number alone hides. In the STEP 1 body-composition analysis, about 39–40% of the weight lost was lean mass, not fat.

The practical consequence: someone who loses weight quickly, loses muscle along with fat, then regains fat later can arrive back at the same number on the scale with a worse body composition than when they started. That person is not imagining the problem, and adding a tape measure, a body-composition measurement or simply how clothes fit gives a truer picture than weight alone. Our guide to muscle loss on Ozempic® goes further into how to protect lean mass during treatment.

What lifestyle modifications can aid in managing Ozempic® related weight gain?

In May 2025, the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association and The Obesity Society published a joint advisory on nutrition during GLP-1 therapy. Its priorities are a good summary of what actually helps:

• Adequate protein, paired with strength training, to preserve lean mass while weight comes down.
• Nutrient-dense, minimally processed food, personalised to the patient rather than a single prescribed diet.
• Attention to micronutrients, since intake falls substantially when appetite does.
• Management of gastrointestinal side effects, which otherwise drive food choices on their own.
• Sleep, activity and stress, all of which influence appetite regulation and weight independently of the medication.

Smaller, more frequent meals and good hydration remain sensible for tolerance. What has changed is the emphasis: protein and resistance training now come first, because they determine what kind of weight is lost.

Compounded and “research” semaglutide: when the dose is unknown

If the product did not come from a licensed pharmacy in its original pen, the dose delivered cannot be assumed. That alone can explain an unexpected weight trend.

This guide deliberately does not publish a conversion from milligrams to “units” or millilitres. Any such figure depends entirely on the concentration of a vial nobody can verify, and would give false confidence about a dose. Anyone using an unverified product should speak with a licensed clinician about moving to a prescribed product.

How can medical care be coordinated to manage weight gain on Ozempic®?

Regular review is what turns an unexplained number on the scale into something actionable. Clinicians, dietitians and exercise professionals each contribute, and the questions worth working through in order are:

1. Confirm the product and its source — pharmacy-dispensed, compounded, or online.
2. Confirm the dose and the gaps — where in titration, how many missed weeks, any interruption in supply.
3. Review every other medication for weight effects, including psychiatric and steroid medicines.
4. Check thyroid function and screen for other contributing conditions.
5. Assess body composition, not weight alone, and set protein and resistance-training targets.
6. Reassess at 12–16 weeks on a full dose before concluding the medication is not working.
7. Plan continuation and maintenance from the first visit, since stopping is what reliably brings the weight back.

For clinicians, this is the difference between managing obesity as a chronic condition and treating a GLP-1 as a course of medication that finishes. If you are building this into a practice, IAPAM’s clinical GLP-1 training is available to sample with the free 1-CME module below.

Free Online GLP-1 Training · Earn 1 CME

Try GLP-1 training free.
Earn 1 CME on us.

Get self-paced access to a real IAPAM provider module covering GLP-1 and GIP receptor agonists, clinical protocols, and patient safety, and claim 1 AMA PRA Category 1 CME™ when you finish. It’s a free sample of our Certified Medical Weight Management Provider™ (CWMP™) program.

What’s Inside Your Free Module

GLP-1 & GIP Receptor AgonistsVideo lectures

Clinical ProtocolsDownloadable resources

Patient SafetyBest practices

1 AMA PRA Cat 1 CME™On completion

Full Module Value$79 — Free

Eligibility: MD/DO, NP, PA, RN

Get Your Free GLP-1 Training + 1 CME

Enter your details and we’ll email your access link.

Frequently Asked Questions

Can Ozempic® make you gain weight?

Weight gain is not a recognised effect of semaglutide itself, and it is not listed as a side effect in the Ozempic® prescribing information. In clinical trials semaglutide consistently produced weight loss. When the scale goes up during treatment, the cause is almost always something alongside the medication: another drug that causes weight gain, a starter dose that has not yet been increased, missed doses, a normal plateau, fluid or constipation, or weight returning after treatment stopped.

Why am I gaining weight on Ozempic® 2 mg?

2 mg once weekly is the maximum approved dose of Ozempic®, but Ozempic® is a type 2 diabetes medication and is not approved for weight loss. The weight-management versions of semaglutide go higher: Wegovy® is approved up to 2.4 mg weekly, and Wegovy® HD up to 7.2 mg weekly since March 2026. Someone at the top of the Ozempic® range has reached the ceiling of that product, not the ceiling of semaglutide. People with type 2 diabetes also lose less weight on the same dose than people without diabetes.

Why have I started gaining weight after a year on Ozempic®?

Weight loss on semaglutide is not endless. In the four-year SELECT trial, weight loss continued for about 65 weeks and then held steady for the rest of the study. Reaching that plateau at around a year is the expected pattern, not a sign the medication stopped working. Small rises after the plateau are usually fluid, food volume, bowel habit or muscle rather than regained fat, although genuine regain can start if doses are being missed or treatment has stopped.

Do you gain the weight back after stopping Ozempic®?

Most people regain a substantial part of it. In the STEP 1 trial extension, participants who lost 17.3% over 68 weeks regained 11.6 percentage points of it in the year after stopping, ending 5.6% below their starting weight. A 2026 BMJ meta-analysis of 37 studies found weight returned at about 0.8 kg a month after stopping semaglutide or tirzepatide, roughly 9.9 kg in the first year, with most people back at their starting weight in about 18 months. Blood pressure, lipids and blood sugar drifted back too.

Why am I gaining weight on semaglutide when I have not changed anything?

The most commonly missed explanation is another medication. Insulin, sulfonylureas, pioglitazone, corticosteroids, several antipsychotics and antidepressants, some anti-seizure medicines and some beta blockers all cause weight gain and will work against a GLP-1. Untreated thyroid disease does the same. A full medication review with the prescriber is the first step, before assuming the semaglutide has failed.

Does Ozempic® cause water retention?

Fluid retention is not a known effect of semaglutide. What people often notice is constipation and bloating, which are common on GLP-1 medications and can add a pound or two to the scale without any change in body fat. True fluid retention, with swollen ankles or sudden weight gain over a few days, points to something else such as heart or kidney disease and should be assessed promptly by a clinician.

What should I do if I’m gaining weight on Ozempic®?

Bring it to the prescriber rather than stopping or changing the dose independently. A useful review covers where you are in titration, any missed or delayed doses, every other medication you take, thyroid function, protein intake and resistance training, and whether the product came from a legitimate pharmacy. Give a full dose 12 to 16 weeks before concluding the medication is not working, since roughly 10 to 15% of people in the trials did not reach 5% weight loss.

Conclusion

Weight going up on Ozempic® is worth investigating, not worth panicking over. The medication itself does not cause weight gain, and in the great majority of cases the explanation is identifiable: a dose that has not reached target, another medication pulling the other way, the plateau that arrives at about a year, muscle lost along with fat, or weight returning after treatment stopped. Each of those has a different answer, which is why the conversation belongs with a prescriber rather than a bathroom scale.

For clinicians, these questions arrive daily now, and answering them well is a large part of running a credible medical weight management service. IAPAM’s GLP-1 certification training for medical weight management providers covers semaglutide and tirzepatide protocols, patient selection, titration, side-effect management and long-term maintenance, with up to 6 AMA PRA Category 1 CME credits online. Many providers pair it with IAPAM’s Botox® training to build a broader aesthetic and wellness practice.

Explore GLP-1 Certification Training →

References

1. Novo Nordisk. Ozempic® (semaglutide) prescribing information (indications, 2 mg maximum dose, 5-day missed-dose window).
2. Novo Nordisk. (2025, January 28). FDA approves Ozempic® to reduce the risk of worsening kidney disease in adults with type 2 diabetes and CKD [Press release].
3. Novo Nordisk. (2025, December 22). FDA approves the Wegovy® pill, oral semaglutide 25 mg (OASIS 4) [Press release].
4. Novo Nordisk. (2026, March 19). FDA approves Wegovy® HD (semaglutide 7.2 mg), STEP UP results [Press release].
5. Davies, M., et al. (2021). Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2). The Lancet, 397(10278), 971–984.
6. Rubino, D., et al. (2021). Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance (STEP 4). JAMA, 325(14), 1414–1425.
7. Wilding, J. P. H., et al. (2022). Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes, Obesity and Metabolism, 24(8), 1553–1564.
8. Ryan, D. H., et al. (2024). Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial. Nature Medicine, 30, 2049–2057.
9. West, S., et al. (2026). Weight regain after cessation of weight management drugs: systematic review and meta-analysis. BMJ, 392, e085304.
10. American College of Lifestyle Medicine, American Society for Nutrition, Obesity Medicine Association & The Obesity Society. (2025, May 30). Nutritional priorities to support GLP-1 therapy for obesity: a joint advisory. The American Journal of Clinical Nutrition.
11. U.S. Food and Drug Administration. (2026, April 30). Proposal to exclude semaglutide, tirzepatide and liraglutide from the 503B bulk drug substances list; reported adverse events involving compounded GLP-1 products.

Disclaimer: The information provided here is for general knowledge only and should not be considered medical advice. For any questions or concerns about your health or medications, please consult your physician or healthcare provider. They are best equipped to provide guidance specific to your medical needs.